POINT Biopharma Global Inc. (PNT) is a clinical-stage pharmaceutical company that focuses on the development and commercialization of radiopharmaceuticals for the treatment of cancer. The company is set to report its earnings on March 24, and analysts are expecting a significant drop in earnings per share. According to analysts' estimates, the company's earnings per share are expected to fall by 70% to -26 cents per share.
This news follows the company's last earnings report on September 30, which showed earnings per share of -86 cents, missing the estimate of -28 cents. This miss in earnings was likely due to the high costs associated with research and development, which is typical for a clinical-stage pharmaceutical company.
Looking at the company's valuation metrics, we can see that the P/B ratio is normal, sitting around the industry mean of 21.747. The P/E ratio of 0.000 is within average values for comparable stocks, averaging 125.520. The projected growth (PEG ratio) of 0.000 is also within normal values, averaging 3.734. However, the company does not pay a dividend, settling around the average of 0.028 among similar stocks. The P/S ratio of 0.000 is also within normal values, averaging 303.071.
Currently, with 607.70K shares outstanding, the company's market capitalization sits at 722.61M.
Despite these metrics, the stock has been in a downward trend, falling for three consecutive days on March 23, 2023. This trend is viewed as bearish, and investors should keep an eye on this stock for future declines. According to data from situations where PNT declined for three days, in 116 of 145 cases, the price declined further within the following month. Therefore, the odds of a continued downward trend are 80%.
We invite you to check out our premium products -- they’ll help you be best prepared to take on the market. One of the premium products that might be helpful for a new trader is the AI Pattern Search Engine. For a continuing trader, AI Real Time Patterns and our Screener, are a great way to pinpoint exactly what you’re looking for and to monitor the securities for an extended period of time.
Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where PNT declined for three days, in of 184 cases, the price declined further within the following month. The odds of a continued downward trend are .
The Momentum Indicator moved below the 0 level on September 05, 2023. You may want to consider selling the stock, shorting the stock, or exploring put options on PNT as a result. In of 60 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The Moving Average Convergence Divergence Histogram (MACD) for PNT turned negative on September 12, 2023. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 29 similar instances when the indicator turned negative. In of the 29 cases the stock turned lower in the days that followed. This puts the odds of success at .
The Aroon Indicator for PNT entered a downward trend on September 20, 2023. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The RSI Indicator shows that the ticker has stayed in the oversold zone for 5 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 9 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where PNT advanced for three days, in of 172 cases, the price rose further within the following month. The odds of a continued upward trend are .
PNT may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.704) is normal, around the industry mean (22.685). P/E Ratio (6.739) is within average values for comparable stocks, (131.324). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.923). Dividend Yield (0.000) settles around the average of (0.033) among similar stocks. P/S Ratio (3.108) is also within normal values, averaging (316.663).
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. PNT’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PNT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 96, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Industry Biotechnology
A.I.dvisor indicates that over the last year, PNT has been loosely correlated with MOR. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if PNT jumps, then MOR could also see price increases.
Ticker / NAME | Correlation To PNT | 1D Price Change % | ||
---|---|---|---|---|
PNT | 100% | -4.16% | ||
MOR - PNT | 48% Loosely correlated | -4.87% | ||
STOK - PNT | 42% Loosely correlated | -6.53% | ||
SLS - PNT | 40% Loosely correlated | +6.67% | ||
LUMO - PNT | 39% Loosely correlated | -3.79% | ||
IOVA - PNT | 38% Loosely correlated | -4.19% | ||
More |